AR074021A1 - Compuestos heterociclicos fusionados como moduladores del canal ionico - Google Patents
Compuestos heterociclicos fusionados como moduladores del canal ionicoInfo
- Publication number
- AR074021A1 AR074021A1 ARP090104206A ARP090104206A AR074021A1 AR 074021 A1 AR074021 A1 AR 074021A1 AR P090104206 A ARP090104206 A AR P090104206A AR P090104206 A ARP090104206 A AR P090104206A AR 074021 A1 AR074021 A1 AR 074021A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- optionally substituted
- aryl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Su uso en el tratamiento de diversos estados patologicos, que incluyen enfermedades cardiovasculares y diabetes. Composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de la formula (1), en donde: R1 es hidrogeno o alquilo C1-6 opcionalmente sustituido con 1, 2 o 3 grupos seleccionados de hidroxilo, alcoxi, halo, -C(O)R, arilo, cicloalquilo, heterociclilo y heteroarilo, en donde dichos grupos arilo, cicloalquilo, heterociclilo o heteroarilo están opcionalmente sustituidos con uno, dos o tres grupos seleccionados, de modo independiente, de halo, hidroxilo, alquilo, -C(O)R, haloalquilo, alcoxi, arilo o cicloalquilo; en donde R es hidroxi, alcoxi o -NH2; R2 y R3 son cada uno, de modo independiente, hidrogeno, halo, alcoxi C1-6, opcionalmente sustituido alquilo C1-6, -CF3, -O-CF 3 o -CN, o R2 y R3, tomados junto con el carbono al que ambos están unidos, forman un cicloalquilo opcionalmente sustituido; R4 es fenilo opcionalmente sustituido con 1, 2 o 3 sustituyentes de modo independiente, seleccionados del grupo que consiste en alquilo C1-6, cicloalquilo, arilo, heteroarilo, heterociclilo, halo, -NO2, -CF3, -O-CF3, -CN, -O-R8, -S-R8, -N(R8)(R9), -S(=O)-R8, -S(=O)2R8, -S(=O)2-N(R8)(R9), -S(=O)2-O-R8, -N(R8)-C(O)-R9, -N(R8)-C(O)-O-R9, -N(R8)-C(O)-NR8)(R9), -C(O)-R8, -C(O)-O-R8, -C(O)-N(R8)(R9) y -N(R8)-S(=O)2-R9, en donde cada uno de dichos alquilo, cicloalquilo, arilo, heteroarilo y heterociclilo también está opcionalmente sustituido con halo, -NO2, -CF3, -O-CF3, -N(R8)(R9), -C(O)-R8, -C(O)-O-R8, -C(O)-N(R8)(R9), -CN, o -O-R8; en donde R8 y R9 están seleccionados, de modo independiente, del grupo que consiste en hidrogeno, alquilo C1-6, heterociclilo, arilo y heteroarilo, en donde el alquilo, heterociclilo, arilo y heteroarilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados, de modo independiente, de halo, alquilo, mono- o dialquilamino, alquilo o arilo, R5 y R6 son cada uno, de modo independiente, hidrogeno, halo, alcoxi, opcionalmente sustituido alquilo C1-6, -CF3, -O-CF3 o -CN, o R5 y R6, tomados junto con el carbono al que ambos están unidos, forman un cicloalquilo opcionalmente sustituido; R7 es hidrogeno, halo, ciano o alquilo C1-6 opcionalmente sustituido con hidroxilo, alcoxi, halo o -C(O)R, X1 y X2 son, de modo independiente, -N= o -C(R10)=, en donde R10 está seleccionado de hidrogeno, halo, hidroxilo, alquilo C1-6, alcoxi C1-6, -CF3, -O-CF3, -CN, o -N(R8)(R9); o una de sus sales, ésteres, profármacos o solvatos farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10978808P | 2008-10-30 | 2008-10-30 | |
| US16101109P | 2009-03-17 | 2009-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074021A1 true AR074021A1 (es) | 2010-12-15 |
Family
ID=41683383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104206A AR074021A1 (es) | 2008-10-30 | 2009-10-30 | Compuestos heterociclicos fusionados como moduladores del canal ionico |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20100113514A1 (es) |
| AR (1) | AR074021A1 (es) |
| TW (1) | TW201028382A (es) |
| WO (1) | WO2010074807A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| GB201106750D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| EA028156B9 (ru) | 2011-05-10 | 2018-01-31 | Джилид Сайэнс, Инк. | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| TWI478908B (zh) * | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NZ627942A (en) | 2012-01-27 | 2016-03-31 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| SG11201604457XA (en) * | 2013-12-19 | 2016-07-28 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| RS57586B1 (sr) * | 2014-01-09 | 2018-11-30 | Orion Corp | Biciklični heterociklični derivati kao inhibitori bromodomena |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| BR112019010880A2 (pt) | 2016-11-28 | 2019-10-01 | Praxis Prec Medicines Inc | compostos e seus métodos de uso |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| CN112423760A (zh) | 2018-05-30 | 2021-02-26 | 普拉克西斯精密药物股份有限公司 | 离子通道调节剂 |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DK0556393T3 (da) | 1990-11-06 | 2000-10-16 | Yamanouchi Pharma Co Ltd | Tilkondenseret pyrazinderivat |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| JPH06228112A (ja) | 1993-02-05 | 1994-08-16 | Yamanouchi Pharmaceut Co Ltd | （１ｈ，４ｈ）キノキサリン誘導体 |
| AU688459B2 (en) | 1994-04-08 | 1998-03-12 | Shionogi & Co., Ltd. | Oxopyridinylquinoxaline derivative |
| MX9702244A (es) | 1994-09-27 | 1997-06-28 | Yamanouchi Pharma Co Ltd | Derivado de 1,2,3,4-tetrahidroquinoxalinadiona. |
| DE19624808A1 (de) | 1996-06-21 | 1998-01-02 | Basf Ag | Pyrrolylchinoxalindione, ihre Herstellung und Verwendung |
| SE9800836D0 (sv) | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
| JP2000281676A (ja) | 1999-01-25 | 2000-10-10 | Yamanouchi Pharmaceut Co Ltd | Ａｍｐａ拮抗化合物の新規製造法 |
| JP2000309586A (ja) | 1999-02-26 | 2000-11-07 | Kyorin Pharmaceut Co Ltd | ６−置換−７−ヘテロキノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法 |
| WO2000066560A1 (en) * | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6498154B1 (en) * | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| AU2002220241A1 (en) | 2000-12-01 | 2002-06-11 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
| JP2004523571A (ja) * | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Ｒｘｒ活性化分子 |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| EP1723146A1 (en) | 2004-03-01 | 2006-11-22 | Eli Lilly And Company | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| RU2007107177A (ru) | 2004-07-28 | 2008-09-10 | Айрм Ллк (Bm) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов |
| US20080176830A1 (en) * | 2005-04-14 | 2008-07-24 | Adams Nicholas D | Compounds, Compositions, and Methods |
| JP2009512637A (ja) * | 2005-09-30 | 2009-03-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 異常脂血症、高コレステロール血症及び糖尿病の処置のためのｒｘｒアゴニストとしてのジヒドロ−［１ｈ］−キノリン−２−オン誘導体 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
-
2009
- 2009-10-28 US US12/607,823 patent/US20100113514A1/en not_active Abandoned
- 2009-10-28 WO PCT/US2009/062386 patent/WO2010074807A1/en active Application Filing
- 2009-10-30 TW TW098136971A patent/TW201028382A/zh unknown
- 2009-10-30 AR ARP090104206A patent/AR074021A1/es unknown
-
2012
- 2012-12-06 US US13/706,786 patent/US8664379B2/en active Active
-
2013
- 2013-12-10 US US14/101,740 patent/US8952007B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140094460A1 (en) | 2014-04-03 |
| TW201028382A (en) | 2010-08-01 |
| US20100113514A1 (en) | 2010-05-06 |
| US8952007B2 (en) | 2015-02-10 |
| WO2010074807A1 (en) | 2010-07-01 |
| US8664379B2 (en) | 2014-03-04 |
| US20130096122A1 (en) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| PH12016501066A1 (en) | ROR GAMMA (ROYy) MODULATORS | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| PE20131143A1 (es) | Nuevas aminopirazoloquinazolinas | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| AR087193A1 (es) | Compuestos fungicidas 2-[2-cloro-4(4-cloro-fenoxi)-fenil]-1-[1,2,4]triazol-1il-etanol alquilo sustituidos | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| TR201900038T4 (tr) | GPR6'nın tetrahidropiridopirazin modülatörleri. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| CR20140091A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| CU23761B7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
| AR085236A1 (es) | Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |